Update regarding Closing of the first stage of the Binding agreement of investment in and acquisition of IOPtima

Tel Aviv (February 11, 2018) – Further to BioLight’s announcement dated November 31, 2017 regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (“the Acquirer”), and in accordance with the Acquirer’s request, the closing of the first stage of the Agreement is extended until March 31st, 2018.
To the complete article

Link to Newsroom

Comments are closed.